JP Morgan Chase
AARD icon

JP Morgan Chase’s Aardvark Therapeutics AARD Stock Holding History

JP Morgan Chase’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$8.72K Sell
1,630
-154
-9% -$939 ﹤0.01% 7172
2026
Q2 		$9.24K Sell
1,784
-4,833
-73% -$22.6K ﹤0.01% 6940
2026
Q1 		$24.1K Sell
6,617
-266
-4% -$2.76K ﹤0.01% 6484
2025
Q4 		$90.3K Buy
6,883
+4,567
+197% +$57K ﹤0.01% 5941
2025
Q3 		$30.8K Sell
2,316
-361
-13% -$4.07K ﹤0.01% 6381
2025
Q2 		$36.2K Sell
2,677
-423
-14% -$4.36K ﹤0.01% 6031
2025
Q1 		$23.3K Buy
+3,100
New +$34.8K ﹤0.01% 6106

Other funds holding AARD

Laurion Capital Management
Laurion Capital Management New York $6.21B AUM 32.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $375B AUM 21.05% 1-Year Est. Return
Jane Street
Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $184B AUM 51.71% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Smith, Moore & Co
Smith, Moore & Co Clayton, Missouri $1.55B AUM 16.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

JP Morgan Chase's AARD Position: Q3 2026 in Review

JP Morgan Chase reduced its Aardvark Therapeutics (AARD) stake by 8.6% in Q3 2026, selling an estimated $939 and leaving 1,630 shares worth $8.72K. The position accounts for ﹤0.01% of the portfolio, ranked #7172.

JP Morgan Chase first reported a position in AARD in Q1 2025 and has held it in 7 quarters since. The position peaked at $90.3K in Q4 2025. 40 funds tracked by Wall St. Rank hold AARD as of Q3 2026.

  • JP Morgan Chase held 1,630 shares of Aardvark Therapeutics worth $8.72K as of Q3 2026.
  • JP Morgan Chase sold 154 Aardvark Therapeutics shares in Q3 2026, an estimated $939.
  • Aardvark Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q3 2026, its #7172 holding.
  • JP Morgan Chase first reported a position in Aardvark Therapeutics in Q1 2025 and has held it in 7 quarters since.
  • JP Morgan Chase's Aardvark Therapeutics position peaked at $90.3K in Q4 2025.
  • 40 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q3 2026.

Based on JP Morgan Chase's 13F filing for Q3 2026, filed 12 Nov 2026.